Monkey IL-5 ELISPOT kit, enzymatic staining
- Known as:
- Monkey Interleukin-5 ELISPOT reagent, enzymatic staining
- Catalog number:
- ct129-pr5
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- U-CyTech biosciences
- Gene target:
- Monkey IL-5 ELISPOT kit enzymatic staining
Related genes to: Monkey IL-5 ELISPOT kit, enzymatic staining
- Gene:
- CSF2RB NIH gene
- Name:
- colony stimulating factor 2 receptor beta common subunit
- Previous symbol:
- IL3RB
- Synonyms:
- IL5RB, CD131, betaGMR
- Chromosome:
- 22q12.3
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2017-07-12
- Gene:
- IL5 NIH gene
- Name:
- interleukin 5
- Previous symbol:
- -
- Synonyms:
- IL-5, EDF, TRF
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2015-07-06
- Gene:
- IL5RA NIH gene
- Name:
- interleukin 5 receptor subunit alpha
- Previous symbol:
- IL5R
- Synonyms:
- CDw125, CD125
- Chromosome:
- 3p26.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-18
- Date modifiied:
- 2016-10-11
- Gene:
- LRR1 NIH gene
- Name:
- leucine rich repeat protein 1
- Previous symbol:
- PPIL5
- Synonyms:
- MGC20689, LRR-1
- Chromosome:
- 14q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-11-20
- Date modifiied:
- 2014-11-18
Related products to: Monkey IL-5 ELISPOT kit, enzymatic staining
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit(1-Kit) 14,15-EET_DHET Hypertension ELISA Kit Related articles to: Monkey IL-5 ELISPOT kit, enzymatic staining
- Intestinal microbial imbalance may cause immune abnormalities, contributing to autism spectrum disorder (ASD). This study investigated immune-related cytokines and T cell subpopulations in children with ASD. - Source: PubMed
Publication date: 2026/08/14
Wu GuihuaShao Yinjin - Interleukin-33 (IL-33) and soluble ST2 (sST2) are critical regulators of tissue-derived inflammation, and their dysregulation is usually implicated in various inflammatory disorders. Despite this, how these circulating proteins behave over time in healthy individuals remains poorly defined. Therefore, defining reference concentrations in healthy cohorts is important for interpreting disease-associated changes attributed to these proteins. - Source: PubMed
Publication date: 2026/08/13
Anabe DeniseTeräsjärvi Johanna TBarkoff Alex-MikaelMertsola JussiHe Qiushui - Allergen challenge to the lung induces oxidative DNA base lesions, including 5-hydroxycytosine (5-OH-Cyt), as well as upregulation of CXC chemokine ligands (CXCLs), both of which have been implicated in allergic inflammation. The precise mechanisms by which specific DNA lesions modulate immune responses and exacerbate allergic lung inflammation remain unclear. This study aimed to investigate the role of 5-OH-Cyt in the CXCL-CXCR1/2-mediated response and its role in promoting Th2 immune responses. - Source: PubMed
Publication date: 2026/08/13
Hosoki KoaGovindhan AnnamalaiChakraborty AnirbanDizdaroglu MiralHazra TapasSur Sanjiv - Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease with a complex pathogenesis that significantly affects patients' quality of life. Type 2 inflammation plays a dominant role in its course and is associated with the activation of immune pathways involving interleukins IL-4, IL-5 and IL-13, eosinophils, and immunoglobulin E. Standard treatment methods, including corticosteroids and surgical interventions, despite their proven efficacy, often fail to provide sustained disease control and are associated with a high rate of recurrence. The aim of this review is not only to summarize the available evidence on biological therapies in CRSwNP, but also to critically evaluate their current position within treatment algorithms, with particular emphasis on patient selection, integration with endoscopic sinus surgery, comparison of available biologic mechanisms, and remaining challenges in personalized treatment strategies. The paper discusses available monoclonal antibodies, such as dupilumab, omalizumab, mepolizumab, and benralizumab, which act by selectively inhibiting key mediators of type 2 inflammation. Analysis of clinical trial results indicates that biological therapies lead to a significant reduction in nasal polyp size, improvement in nasal patency, restoration of olfactory function, and enhancement of quality of life as measured by the SNOT-22 scale. Furthermore, they demonstrate a favourable safety profile and may represent an effective therapeutic option for patients with severe, treatment-resistant disease, particularly in cases with coexisting eosinophilic asthma. Biological therapies represent a breakthrough in the treatment of CRSwNP and align with the concept of personalised medicine. Their role in clinical practice continues to expand; however, further research is required to optimise patient selection and assess long-term treatment outcomes. - Source: PubMed
Publication date: 2026/07/26
Wrona JoannaKrupa ZuzannaZawadzka MartaRydzek JuliaMuzyka AdrianDorobisz KarolinaPazdro-Zastawny Katarzyna - Prabchompoothaweep (PCT) is an anti-allergic remedy on the Thailand National List of Essential Medicines, traditionally used to relieve common colds and allergic reactions in Thai traditional medicine (TTM). However, the anti-allergic activity of PCT and its plant ingredients had not been characterized. We evaluated the acute and chronic oral toxicity of PCT ethanolic extract in rats and assessed its in vitro and in vivo anti-allergic activities. Activity in vitro was measured as inhibition of antigen-induced β-hexosaminidase release in RBL-2H3 cells and in vivo using an ovalbumin (OVA)-induced allergic rhinitis mouse model. The extract produced no mortality or signs of toxicity in either study. Several plant ingredients and the PCT extract inhibited β-hexosaminidase release more effectively than chlorpheniramine. In OVA-induced mice, PCT (75, 150, and 300 mg/kg) did not significantly lower OVA-specific serum IgE or IgG2a (OVA-specific IgG1 was likewise not reduced); however, it reduced inflammatory cell infiltration, goblet cell hyperplasia and mast cell numbers in the nasal mucosa and downregulated the T helper 2 (Th2) cytokines IL-5 and IL-13. These findings support the traditional anti-allergic use of the PCT remedy. - Source: PubMed
Publication date: 2026/08/05
Makchuchit SunitaPusiripinyo PattarapolJai-Uea AreeratnaKuropakornpong PranpornSireeratawong SeewaboonKhonsung PariratDavies Neal MItharat Arunporn